E/M Coding Alert - 2005 Issue 1
PRESCRIPTION DRUGS: More Drugs? Fewer Drugs? Formulary Debate Rages On
Subscribe or sign in to view the full article.
Article Overview
This article examines the ongoing debate surrounding Medicare prescription-drug plan formularies as the full benefit approaches. It focuses on how health plans, pharmacy benefit managers, pharmaceutical manufacturers, and standards-setting organizations are positioning themselves, and why the structure of formulary guidance matters to sponsors, regulators, and beneficiaries.
Why This Topic Matters
The discussion affects how prescription drug coverage is organized in Medicare private plans and drug plans, with implications for plan flexibility, market competition, and oversight by CMS. It is relevant to health plans, PBMs, pharmaceutical companies, employer groups, and policy professionals tracking Medicare benefit implementation.
What You Will Learn
- How stakeholders are arguing over Medicare prescription-drug formulary structure
- Why formulary guidance is being treated as a major policy and market issue
- Which organizations are involved in developing, defending, or criticizing the guidance
- How the debate relates to CMS oversight and plan design flexibility
Who Should Read This
- Health plan executives
- Pharmacy benefit managers
- Pharmaceutical industry professionals
- Medicare policy analysts
- Employer-sponsored retiree benefit administrators
- Medical coding and reimbursement professionals monitoring policy changes
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com